当前位置： SCI文献检索 > Cancer Discovery期刊下所有文献 > BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.

BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.

Abstract：

: BRAF fusions and mutations are the most frequent genetic alterations in pediatric low-grade gliomas. The work from Wang and colleagues identifies an acquired secondary BRAF mutation that confers resistance to pharmacologic BRAF inhibition in a BRAFV600E glioma. The authors demonstrate that the mutation results in increased BRAF homodimerization, which in turn is targetable with second-generation BRAF inhibitors. Cancer Discov; 8(9); 1064-5. ©2018 AACR.See related article by Wang et al., p. 1130.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

Romano G,Kwong LN

doi

10.1158/2159-8290.CD-18-0784

subject

Has Abstract

pub_date

2018-09-01 00:00:00

pages

1064-1065

issue

9

eissn

2159-8274

issn

2159-8290

pii

8/9/1064

journal_volume

8

pub_type

评论,杂志文章

相关文献

Cancer Discovery文献大全
  • Engineering Multidimensional Evolutionary Forces to Combat Cancer.

    abstract：:With advances in technology and bioinformatics, we are now positioned to view and manage cancer through an evolutionary lens. This perspective is critical as our appreciation for the role of tumor heterogeneity, tumor immune compartment, and tumor microenvironment on cancer pathogenesis and evolution grows. Here, we e...

    journal_title：Cancer discovery

    pub_type： 杂志文章,评审

    doi：10.1158/2159-8290.CD-18-1196

    authors： McCoach CE,Bivona TG

    更新日期：2019-05-01 00:00:00

  • AMG 510 First to Inhibit "Undruggable" KRAS.

    abstract：:Amgen's novel small-molecule inhibitor AMG 510 has become the first drug to successfully target a KRAS mutation in patients, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRASG1...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2019-073

    authors：

    更新日期：2019-08-01 00:00:00

  • Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.

    abstract：UNLABELLED:Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) profiling of small-molecule sensitivity has emerged as an unbiased method to assess the relationships between genetic or c...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-15-0235

    authors： Seashore-Ludlow B,Rees MG,Cheah JH,Cokol M,Price EV,Coletti ME,Jones V,Bodycombe NE,Soule CK,Gould J,Alexander B,Li A,Montgomery P,Wawer MJ,Kuru N,Kotz JD,Hon CS,Munoz B,Liefeld T,Dančík V,Bittker JA,Palmer M,

    更新日期：2015-11-01 00:00:00

  • Panel OKs CAR T Therapy for Leukemia.

    abstract：:An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The therapy would be the first of its kind approved for cancer and has the potential to transform standard of...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-108

    authors：

    更新日期：2017-09-01 00:00:00

  • Niraparib Slows Ovarian Cancer Progression.

    abstract：:Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer. Improved progression-free survival was seen regardless of the presence or absence of germline BRCA mutations, or o...

    journal_title：Cancer discovery

    pub_type：

    doi：10.1158/2159-8290.CD-NB2016-137

    authors：

    更新日期：2016-12-01 00:00:00

  • A Set of Transcriptomic Changes Is Associated with Anti-PD-1 Resistance.

    abstract：:The IPRES signature is related to anti-PD-1 response, and high mutational load predicts survival. ...

    journal_title：Cancer discovery

    pub_type： 信件

    doi：10.1158/2159-8290.CD-RW2016-057

    authors：

    更新日期：2016-05-01 00:00:00

  • Clonal evolution: multiregion sequencing of esophageal adenocarcinoma before and after chemotherapy.

    abstract：:It is possible to decipher the clonal architecture of a tumor and the sequence in which cancer clones acquire genomic alterations through multiregion sequencing (M-seq). Serial evaluation of tumor specimens through M-seq can provide valuable information on the molecular basis of resistance to therapy. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-15-0739

    authors： Devarakonda S,Govindan R

    更新日期：2015-08-01 00:00:00

  • Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond.

    abstract：:Hallin and colleagues demonstrate the preclinical activity of the KRASG12C-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRASG12C inhibition highlights both the promise and potential need for combinatorial strat...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-19-1255

    authors： Klempner SJ,Hata AN

    更新日期：2020-01-01 00:00:00

  • Pembrolizumab Shows Promise for NSCLC.

    abstract：:Data from the KEYNOTE-001 trial show that pembrolizumab improves clinical outcomes for patients with advanced non-small cell lung cancer, and is well tolerated. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2015-057

    authors：

    更新日期：2015-06-01 00:00:00

  • Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

    abstract：:Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alt...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-18-0275

    authors： Aguirre AJ,Nowak JA,Camarda ND,Moffitt RA,Ghazani AA,Hazar-Rethinam M,Raghavan S,Kim J,Brais LK,Ragon D,Welch MW,Reilly E,McCabe D,Marini L,Anderka K,Helvie K,Oliver N,Babic A,Da Silva A,Nadres B,Van Seventer EE,

    更新日期：2018-09-01 00:00:00

  • Genomic Screens Identify Genes That Regulate MHC-I Expression in DLBCL.

    abstract：:MHC-I and MHC-II regulators in lymphomas, some of which had subtype or tumor specificity, were identified. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-RW2020-178

    authors：

    更新日期：2020-12-11 00:00:00

  • STATe-of-the-art approach: using oligonucleotide decoys to target the "undruggable".

    abstract：:Sen and colleagues have shown for the first time the clinical application of an oligonucleotide decoy targeting the oncogenic transcription factor STAT3 for the treatment of head and neck tumors. Intratumoral injection of decoy effectively reduced the activity of STAT3 as evidenced by a decrease in several of its tran...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-12-0310

    authors： Koppikar P,Bromberg J

    更新日期：2012-08-01 00:00:00

  • First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.

    abstract：:Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects and replication stress, including inactivation of ataxia telangiectasia mutated (ATM) signaling. We report the dose-escalation portion of the phase I first-in-h...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-20-0868

    authors： Yap TA,Tan DSP,Terbuch A,Caldwell R,Guo C,Goh BC,Heong V,Haris NRM,Bashir S,Drew Y,Hong DS,Meric-Bernstam F,Wilkinson G,Hreiki J,Wengner AM,Bladt F,Schlicker A,Ludwig M,Zhou Y,Liu L,Bordia S,Plummer R,Lagkadin

    更新日期：2020-09-28 00:00:00

  • XPO1 Inhibitor Approved for Multiple Myeloma.

    abstract：:The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2019-085

    authors：

    更新日期：2019-09-01 00:00:00

  • Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.

    abstract：: In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the centra...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-17-0714

    authors： Lakshmanan A,Byrd JC

    更新日期：2017-09-01 00:00:00

  • Widespread Genomic Testing Deemed Feasible.

    abstract：:Although comprehensive genomic screening has not yet become routine when treating patients with cancer, widespread testing in those with advanced, refractory disease is feasible, according to the ongoing ProfiLER study. The study also found that patients who subsequently received a treatment matched to the genetic cha...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-094

    authors：

    更新日期：2017-08-01 00:00:00

  • A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

    abstract：UNLABELLED:Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients with prostate cancer, acquired resistance invariably emerges. To identify the molecular mechanisms underlying acquired resistance, we developed and characterized cell lines resistant to ARN-50...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-13-0226

    authors： Joseph JD,Lu N,Qian J,Sensintaffar J,Shao G,Brigham D,Moon M,Maneval EC,Chen I,Darimont B,Hager JH

    更新日期：2013-09-01 00:00:00

  • Targeting HDAC And PI3K Inhibits MYC-Driven Medulloblastoma Growth.

    abstract：:HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...

    journal_title：Cancer discovery

    pub_type： 评论,信件

    doi：10.1158/2159-8290.CD-RW2016-052

    authors：

    更新日期：2016-05-01 00:00:00

  • Cryo-Electron Microscopy Reveals Architecture of the BAF Complex.

    abstract：:The structure of the chromatin-remodeling BAF complex provides molecular-scale mechanistic insight. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2020-020

    authors：

    更新日期：2020-03-01 00:00:00

  • High ORRs Seen with Tagraxofusp-erzs in BPDCN.

    abstract：:Tagraxofusp-erzs is an effective therapy for blastic plasmacytoid dendritic-cell neoplasm, according to recently published results from a multistage trial that led to the drug's 2018 approval. In the trial, the drug elicited high overall response rates, and many patients went on to receive a stem-cell transplant. Howe...

    journal_title：Cancer discovery

    pub_type： 评论,新闻

    doi：10.1158/2159-8290.CD-NB2019-061

    authors：

    更新日期：2019-07-01 00:00:00

  • Second-generation ALK inhibitors: filling the non "MET" gap.

    abstract：:Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provi...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-14-0410

    authors： Ramalingam SS,Khuri FR

    更新日期：2014-06-01 00:00:00

  • Antibody-Drug Conjugate Kills Neuroblastoma Cells.

    abstract：:Researchers have developed an antibody-drug conjugate with the potential to treat neuroblastoma. The agent targets ALK, which is found on neuroblastoma cells but not healthy cells, delivering a drug that causes DNA cross-links. Researchers have found that the antibody-drug conjugate kills ALK-expressing cells in vitro...

    journal_title：Cancer discovery

    pub_type： 评论,新闻

    doi：10.1158/2159-8290.CD-NB2019-052

    authors：

    更新日期：2019-06-01 00:00:00

  • Desmoid Tumors Respond to Sorafenib.

    abstract：:A recent clinical trial shows that sorafenib is effective against desmoid tumors. The study found that 33% of tumors shrank in patients who received the drug. The estimated 1-year progression-free survival for the sorafenib-treated patients was 89%, and the 2-year rate was 81%. ...

    journal_title：Cancer discovery

    pub_type： 评论,新闻

    doi：10.1158/2159-8290.CD-NB2019-004

    authors：

    更新日期：2019-03-01 00:00:00

  • A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

    abstract：:Activation of AKT signaling by PTEN loss or PIK3CA mutations occurs frequently in human cancers, but targeting AKT has been difficult due to the mechanism-based toxicities of inhibitors that target the inactive conformation of AKT. Ipatasertib (GDC-0068) is a novel selective ATP-competitive small-molecule inhibitor of...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-16-0512

    authors： Saura C,Roda D,Roselló S,Oliveira M,Macarulla T,Pérez-Fidalgo JA,Morales-Barrera R,Sanchis-García JM,Musib L,Budha N,Zhu J,Nannini M,Chan WY,Sanabria Bohórquez SM,Meng RD,Lin K,Yan Y,Patel P,Baselga J,Tabernero J,

    更新日期：2017-01-01 00:00:00

  • ZNF365 promotes stability of fragile sites and telomeres.

    abstract：:Critically short telomeres activate cellular senescence or apoptosis, as mediated by the tumor suppressor p53, but in the absence of this checkpoint response, telomere dysfunction engenders chromosomal aberrations and cancer. Here, analysis of p53-regulated genes activated in the setting of telomere dysfunction identi...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-12-0536

    authors： Zhang Y,Shin SJ,Liu D,Ivanova E,Foerster F,Ying H,Zheng H,Xiao Y,Chen Z,Protopopov A,Depinho RA,Paik JH

    更新日期：2013-07-01 00:00:00

  • IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

    abstract：:Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic stroma. Within the stroma, cancer-associated fibroblasts (CAF) secrete tropic factors and extracellular matrix components, and have been implicated in...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-18-0710

    authors： Biffi G,Oni TE,Spielman B,Hao Y,Elyada E,Park Y,Preall J,Tuveson DA

    更新日期：2019-02-01 00:00:00

  • Cause of Early-Onset Colorectal Cancer Multifactorial.

    abstract：:A report from the American Cancer Society reveals that colorectal cancer in people younger than 50 continues to increase, a trend that has spread to the 50-to-64 age group for the first time. Multiple lines of evidence indicate that obesity, often pinpointed as the cause, is not the only contributor. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2020-016

    authors：

    更新日期：2020-06-01 00:00:00

  • Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma.

    abstract：:MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the pancreatic phenotypes arisin...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-19-0620

    authors： Muthalagu N,Monteverde T,Raffo-Iraolagoitia X,Wiesheu R,Whyte D,Hedley A,Laing S,Kruspig B,Upstill-Goddard R,Shaw R,Neidler S,Rink C,Karim SA,Gyuraszova K,Nixon C,Clark W,Biankin AV,Carlin LM,Coffelt SB,Sansom OJ,

    更新日期：2020-06-01 00:00:00

  • Evolutionary pathways in BRCA1-associated breast tumors.

    abstract：:BRCA1-associated breast tumors display loss of BRCA1 and frequent somatic mutations of PTEN and TP53. Here we describe the analysis of BRCA1, PTEN, and p53 at the single cell level in 55 BRCA1-associated breast tumors and computational methods to predict the relative temporal order of somatic events, on the basis of t...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-11-0325

    authors： Martins FC,De S,Almendro V,Gönen M,Park SY,Blum JL,Herlihy W,Ethington G,Schnitt SJ,Tung N,Garber JE,Fetten K,Michor F,Polyak K

    更新日期：2012-06-01 00:00:00

  • Cancer Care Goes Virtual in Response to COVID-19.

    abstract：:Amid concerns over the spread of COVID-19, oncology practices have "gone virtual," with video appointments scheduled for any service that does not require diagnostic testing or treatment. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2020-027

    authors：

    更新日期：2020-06-01 00:00:00